Regeneron Pharmaceuticals Business Operations Contracts & Agreements
34 Contracts & Agreements
- Collaboration Agreements (19 contracts)
- Development Agreements (4)
- Settlement Agreements (2)
- Supply Agreements (7)
- Termination Agreements (2)
- First Amendment to Amended and Restated License and Collaboration Agreement by and between the Registrant and Aventis Pharmaceuticals Inc., dated May 1, 2013 (Filed With SEC on August 3, 2023)
- Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)
- Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)
- Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)
- Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)
- Fifth Amendment to Amended and Restated License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi (Filed With SEC on August 3, 2022)
- Amended and Restated Immuno-Oncology License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on August 3, 2022)
- Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on May 4, 2022)
- First Amendment to Immuno-oncology License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on February 7, 2022)
- Fourth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi (Filed With SEC on February 7, 2022)
- Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 4, 2021)
- Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and the U.S. Army Contracting Command, New... (Filed With SEC on November 4, 2021)
- Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi... (Filed With SEC on August 5, 2020)
- Form of Co-Co Collaboration Agreement (Exhibit B to Master Agreement contained in Exhibit 10.4) (Filed With SEC on August 6, 2019)
- Amended and Restated Immuno-oncology Discovery and Development Agreement, executed on January 2, 2019 and effective as of December 31, 2018, by and between the Registrant and... (Filed With SEC on February 7, 2019)
- AMENDMENT NO. 2 TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 4, 2015)
- AMENDMENT NO. 1 TO AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (Filed With SEC on November 4, 2015)
- AMENDED AND RESTATED COLLABORATION AGREEMENT By and Between SANOFI-AVENTIS US, LLC and REGENERON PHARMACEUTICALS, INC. Dated as of February 23, 2015 TABLE OF CONTENTS (Filed With SEC on May 7, 2015)
- NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENT (Filed With SEC on August 6, 2013)
- AMENDED AND RESTATED NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENT (Filed With SEC on August 6, 2013)
- FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 6, 2013)
- AMENDED AND RESTATEDDISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT By and Between AVENTIS PHARMACEUTICALSINC. and REGENERON PHARMACEUTICALS,INC. Dated as of November 10, 2009... (Filed With SEC on February 18, 2010)
- TRAP -2 TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009 (Filed With SEC on August 4, 2009)
- IL-1 ANTIBODY TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009 (Filed With SEC on August 4, 2009)
- LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on February 27, 2008)
- DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (Filed With SEC on February 27, 2008)
- EX-10.1: LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 6, 2006)
- EX-10.13.4: AMENDMENT NO. 4 TO COLLABORATION AGREEMENT (Filed With SEC on February 28, 2006)
- EX-10.13.3: AMENDMENT NO. 3 TO COLLABORATION AGREEMENT (Filed With SEC on February 28, 2006)
- AMENDMENT NO. 1 TO COLLABORATION AGREEMENT (Filed With SEC on March 11, 2005)
- SECOND AMENDMENT TO COLLABORATION AGREEMENT (Filed With SEC on January 11, 2005)
- COLLABORATION AGREEMENT (Filed With SEC on November 12, 2003)
- COLLABORATION, LICENSE AND OPTION AGREEMENT (Filed With SEC on May 15, 2003)
- EX-10.22: FOCUSED COLLABORATION AGREEMENT (Filed With SEC on August 13, 2002)
